New nanovaccine aims to stop cancer recurrence in High-Risk patients
NCT ID NCT07353645
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new nanovaccine made from engineered bacteria that targets KRAS mutations in colorectal and pancreatic cancer patients who have had surgery and chemotherapy but are at high risk of their cancer coming back. The vaccine is designed to train the immune system to recognize and attack cancer cells carrying these mutations. The trial will check if the vaccine is safe and whether it can reduce or clear signs of remaining cancer in the blood.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanjing Drum Tower Hospital Affiliated to Medical School of Nanjing University
RECRUITINGNanjing, Jiangsu, 210008, China
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict who will survive a bowel surgery leak?
- Can High-Dose vitamin c boost Chemo's punch against pancreatic cancer?
- Can a Two-Drug attack shrink Hard-to-Treat colorectal tumors?
- Can a cancer pill keep working outside the lab? a Real-World test begins
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- A mobile app aims to turn health awareness into action — a trial puts it to the test